Evidence map›Paper›PMID 32144692›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2020

Short communication: a modified Vaccinia virus Ankara-based Porcine circovirus 2 vaccine elicits strong antibody response upon prime-boost homologous immunization in a preclinical model.

Danielle Soares de Oliveira Daian E Silva, Edel Figueiredo Barbosa-Stancioli, Jordana Graziela Alves Coelho-Dos-Reis, Flávio Guimarães Da Fonseca

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Danielle Soares de Oliveira Daian E SilvaLaboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte, MG, CEP: 31270-901, Brazil.
Edel Figueiredo Barbosa-StancioliLaboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte, MG, CEP: 31270-901, Brazil.
Jordana Graziela Alves Coelho-Dos-ReisLaboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte, MG, CEP: 31270-901, Brazil.
Flávio Guimarães Da FonsecaLaboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte, MG, CEP: 31270-901, Brazil. fdafonseca@icb.ufmg.br.ORCID http://orcid.org/0000-0002-1416-8694
Universidade Federal de Minas Gerais · BR

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (BR) Dont appliedHERTAPE SAÚDE ANIMAL Dont applied
6 · The paper itself

Abstract

Porcine circovirus 2 (PCV2) infections are related to a number of syndromes and clinical manifestations, generally known as Porcine circovirus-associated diseases, which are related to losses in the swine industry. There are commercially available vaccines and new vaccines being tested, however, persistency of the PCV2 as an important pig pathogen, and the growing number of affected farms in different countries have suggested that there is room for vaccine improvement. In this study, we describe the construction and testing of a recombinant live vaccine based on a modified Vaccinia virus Ankara (MVA) vector expressing the PCV2b capsid protein (CAP). Using a two-dose homologous vaccination regimen, in mice, we demonstrated that the vaccine induced high titers of anti-PCV2 antibodies. The vaccine is stable upon lyophilization, and, together with the good immunogenicity potential observed, the results support further evaluation of the MVA-CAP vaccine in the target species.

Indexed as

AnimalsAntibodies, ViralAntibody FormationCircoviridae InfectionsCircovirusImmunization, SecondarySwineSwine DiseasesVaccinationVaccines, AttenuatedVaccinia virusViral VaccinesAntibodies, ViralVaccines, AttenuatedViral VaccinesCapsid proteinHomologous vaccination regimenModified Vaccinia virus Ankara (MVA)Porcine circovirus 2Recombinant vaccine

Identifiers

PMID32144692
PMCPMC7455681
OpenAlexW3009332338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.